Disrupting persistent TLR4 signaling with TLR4 inhibitors therefore might represent a potential strategy for breaking the vicious fibrosis cycle in SSc or other fibrotic diseases (7, 8). This evidence concerns the gene TLR4 and systemic sclerosis.